Overview
ANIP market data
Price History
ANIP price chart
Valuation & Profitability
- P/E (TTM)
- 18.72 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $3.69 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.50 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- 0.0% Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 10.0% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $70.15 – $99.50 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $1.7B · P/B 3.28 · P/S 1.87.
Company News
These Analysts Slash Their Forecasts On ANI Pharmaceuticals After Q2 ResultsBenzinga · Aug 10, 2026, 2:39 PM
Guggenheim Maintains Buy on ANI Pharmaceuticals, Lowers Price Target to $119Benzinga · Aug 10, 2026, 2:07 PM
Canaccord Genuity Maintains Hold on ANI Pharmaceuticals, Lowers Price Target to $90Benzinga · Aug 10, 2026, 12:27 PM
ANI Pharmaceuticals shares are trading lower despite reporting better-than-expected Q2 results, possibly dragged down by lowered Cortrophin outlook, margin compression, and rising costs.Benzinga · Aug 7, 2026, 6:26 PM
8-K filing — ANI PHARMACEUTICALS INC (ANIP)SEC EDGAR · Aug 7, 2026, 11:00 AM
ANI Pharmaceuticals Affirms FY2026 Adj EPS Guidance of $9.19-$9.69 vs $9.45 Est; Affirms FY2026 Sales Guidance of $1.080B-$1.140B vs $1.119B EstBenzinga · Aug 7, 2026, 10:53 AM
ANI Pharmaceuticals Q2 Adj. EPS $2.21 Beats $2.05 Estimate, Sales $266.044M Beat $260.128M EstimateBenzinga · Aug 7, 2026, 10:50 AM
ANI Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 7, 2026 at 8:00 a.m. ETGlobenewswire Inc · Jul 24, 2026, 11:15 AM
Two Years to Build or Pay 200% — Which US Pharma Stocks Win?Benzinga · Jul 24, 2026, 10:25 AM
Shares of generic drug companies are trading lower after President Trump announced that imported generics will be subject to a 100% import tariff following a two-year grace period in order to encourage reshoring of pharma manufacturing.Benzinga · Jul 22, 2026, 4:27 PM